Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 30,000 shares at $48.72 ($1.5M) on 2025-01-08, disclosed to the SEC on 2025-01-10.
Scheduled sale ($1.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.72 | 12,132 | $591K | 40.3% |
| 2 | $48.72 | 12,132 | $591K | 40.3% |
| 3 | $49.38 | 2,868 | $142K | 9.7% |
| 4 | $49.38 | 2,868 | $142K | 9.7% |
| Total | $48.85 avg | 30,000 | $1.5M | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |